as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹107.71
Change
+2.69 (2.56%)
Open
₹105.5
Prev. Close
₹105.02
Day High
₹112.35
Day Low
₹105.5
Volume Analysis
Traded
62,694
Delivered
24,463
Delivery %
39.02%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •High debt-to-equity ratio (1.95)
- •Low return on equity (7.87%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (41/100)
Opportunities (1)
- •Strong 3-year EPS growth (33.9%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹118.39 | ₹115.37 | ₹111.54 | ₹108.52 | ₹104.69 | ₹101.67 | ₹97.84 |
| Fibonacci | ₹115.37 | ₹112.75 | ₹111.14 | ₹108.52 | ₹105.9 | ₹104.29 | ₹101.67 |
| Camarilla | ₹109.59 | ₹108.97 | ₹108.34 | ₹108.52 | ₹107.08 | ₹106.45 | ₹105.83 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+47.51%
1 Week
-1.52%
1 Month
+27.02%
3 Months
+35.4%
6 Months
+66.04%
1 Year
+29.94%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹67.63
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.0%
Net margin 2.1% × asset turnover 0.83x × equity multiplier 4.59x
Company Overview
Sector
Healthcare
Market Cap
₹175 Cr
P/E (TTM)
24.4
ROE
7.87%
Book Value
₹51.6
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Bal Pharma Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 41/100. The strongest factor is Momentum (77/100), while Financial Strength (3/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (1.95); low return on equity (7.87%). Strong 3-year EPS growth (33.9%).
TopFund Score — Fundamentals Quality
41/100 — WeakData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 27.5%
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 4.46% over past five years.
- −Tax rate seems low
- −Company has a low return on equity of 9.37% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Trading window closed from October 1, 2026 until 48 hours after Q2 FY2027 results.
Bal Pharma held its 39th AGM on September 24, 2026, approving FY26 accounts and Rs.1.20 dividend.
Bal Pharma clarifies no price-sensitive event behind scrip movement on September 10, 2026.
Exchange has sought clarification from Bal Pharma Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors …
Bal Pharma allotted 10 lakh warrants to promoter Shailesh Siroya for ₹8.4 crore at ₹84 each.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 70 | 93 | 82 | 95 | 74 | 74 | 73 | 82 | 66 | 74 | 88 | 84 | 89 |
| Expenses + | 64 | 85 | 74 | 85 | 68 | 66 | 65 | 74 | 60 | 68 | 78 | 74 | 81 |
| Operating Profit | 6 | 8 | 8 | 10 | 6 | 8 | 8 | 8 | 6 | 6 | 10 | 11 | 8 |
| OPM % | 9.15% | 8.32% | 9.54% | 10.14% | 8.7% | 10.44% | 10.59% | 9.33% | 9.2% | 7.74% | 10.88% | 12.58% | 8.97% |
| Other Income + | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Interest | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 |
| Depreciation | 3 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 3 | 3 | 3 |
| Profit before tax | 0 | 2 | 1 | 6 | 1 | 1 | 1 | 3 | 0 | 1 | 2 | 3 | 1 |
| Tax % | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0.0% | 0.0% | 0.0% | -12.11% | 0.0% |
| Net Profit + | 0 | 1 | 1 | 6 | 0 | 1 | 1 | 5 | 0 | 1 | 2 | 4 | 1 |
| EPS in Rs | 0 | 1 | 1 | 3 | 0 | 1 | 0 | 3 | 0 | 0 | 1 | 2 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 312 | 334 |
| Expenses + | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 280 | 301 |
| Operating Profit | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 32 | 34 |
| OPM % | 9.0% | 7.0% | 6.0% | 8.0% | 8.0% | 2.9% | 10.0% | 9.0% | 8.0% | 9.0% | 10.0% | 10.0% | 10.0% |
| Other Income + | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 2 | 2 |
| Interest | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 | 17 |
| Depreciation | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 11 | 11 |
| Profit before tax | 5 | 3 | 3 | 3 | 0 | -14 | 4 | 9 | 5 | 9 | 5 | 6 | 7 |
| Tax % | 25.0% | 90.0% | 114.0% | 87.0% | -1,175.0% | -5.0% | -15.0% | 38.0% | 45.0% | 18.0% | -41.0% | -7.0% | — |
| Net Profit + | 4 | 1 | 0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 6 | 7 |
| EPS in Rs | 3 | 1 | 1 | 2 | 3 | -9 | 3 | 4 | 2 | 5 | 5 | 4 | 5 |
| Dividend Payout % | 35.0% | 91.0% | 81.0% | 51.0% | 37.0% | 0.0% | 31.0% | 26.0% | 61.0% | 26.0% | 26.0% | 30.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 66 |
| Borrowings + | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 160 |
| Other Liabilities + | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 134 |
| Total Liabilities | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Fixed Assets + | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 94 |
| CWIP | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 2 |
| Other Assets + | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 272 |
| Total Assets | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Equity Capital | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 15 | -19 | 6 | 1 | 8 | 23 | 22 | 27 | -2 | 23 | 20 | 30 |
| Cash from Investing Activity + | -5 | -14 | -8 | -4 | -8 | -5 | -6 | -9 | -22 | -19 | -15 | -21 |
| Cash from Financing Activity + | -7 | 32 | -6 | 4 | 0 | -20 | -17 | -17 | 24 | -1 | -8 | -10 |
| Net Cash Flow | 2 | -1 | -8 | 1 | 0 | -2 | 0 | 0 | 0 | 3 | -2 | 0 |
| CFO/OP | 93 | -125 | 52 | 11 | 57 | 465 | 91 | 117 | -4 | 88 | 75 | 95 |
| Free Cash Flow | 9 | -34 | -2 | -3 | -1 | 18 | 19 | 18 | -16 | 12 | 2 | 8 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 48.25% | 48.64% | 48.64% | 48.63% | 49.01% | 49.0% | 49.01% | 48.99% | 48.91% | 49.01% | 49.01% | 48.99% |
| Promoters | 51.61% | 51.24% | 51.24% | 51.24% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% | 50.87% |
| FII | 0.14% | 0.13% | 0.13% | 0.13% | 0.13% | 0.14% | 0.14% | 0.15% | 0.23% | 0.14% | 0.14% | 0.15% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Bal Pharma Ltd. (this stock) | 175 | 24.4 | 2.13 | 7.87% |
| Natural Capsules Limited | 176 | — | 1.01 | -9.45% |
| Brooks Lab Limited | 180 | 13.7 | 1.47 | 22.0% |
| Parnax Lab Ltd. | 149 | 14.8 | 1.56 | 14.4% |
| Nectar Lifesciences Ltd. | 211 | — | 0.36 | -31.3% |
| Balaxi Pharma Ltd | 126 | 52.0 | 0.51 | 0.59% |
| Alpa Laboratories Ltd | 124 | 30.6 | 0.67 | 8.39% |
Which Mutual Funds Hold Bal Pharma Ltd.?
Frequently Asked Questions about Bal Pharma Ltd.
Bal Pharma Ltd. (BALPHARMA) closed at ₹107.71 on NSE on 25 September 2026, up 2.69 (2.56%) from the previous close.
Bal Pharma Ltd. trades on the NSE (National Stock Exchange of India) under the symbol BALPHARMA.
Bal Pharma Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 24.4.
Bal Pharma Ltd. has a dividend yield of 1.1%.
Bal Pharma Ltd.'s 52-week high is ₹125.0 and its 52-week low is ₹59.7.
Bal Pharma Ltd. has a market capitalisation of ₹175 crore.
Bal Pharma Ltd. has a TopFund Quality Score of 41/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Bal Pharma Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.